Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme

Familial Cancer

Volumn 13, Issue 2, 2014, Pages 189-196

  Evans, D Gareth R ^a,b,c   Ingham, Sarah ^a,d   Dawe, Sarah ^a   Roberts, L ^a   Lalloo, F ^b   Brentnall, A R ^e   Stavrinos, P ^a,c   Howell, Anthony ^a,c  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer; Claus; Prospective; Risk estimation; Tyrer Cuzick

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CALIBRATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; FAMILY HISTORY; FEMALE; FOLLOW UP; GENETIC RISK; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MANUAL MODEL; MODEL; PRIORITY JOURNAL; REPRODUCTION; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM; BREAST NEOPLASMS; EARLY DIAGNOSIS; GENETICS; INCIDENCE; MIDDLE AGED; PROCEDURES; THEORETICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; INCIDENCE; MIDDLE AGED; MODELS, THEORETICAL; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84903304106     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-013-9694-z     Document Type: Article

References (26)

1. Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early onset breast cancer: implications for risk prediction. Cancer 73:643-651 (Pubitemid 24046606)
2. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829-1846
3. Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77(11):2318-2324 (Pubitemid 26162426)
4. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676-689 (Pubitemid 28164626)
5. Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145-158 (Pubitemid 28093844)
6. The University of Texas Southwestern Medical Center at Dallas. CancerGene. Available at http://www4.utsouthwestern.edu/breasthealth/cagene/ CGdownload.asp
7. Tyrer JP, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111-1130 (Pubitemid 38477070)
8. Cuzick J, Howell A, Powles T, Forbes J, Baum M (2002) First results from the International breast cancer intervention study (IBIS-I): a randomised prevention trial. Lancet 360:817-824 (Pubitemid 35257944)
9. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40(11):807-814 (Pubitemid 37485490)
10. Cyrillic 3.0 pedigree software. Accessed on March 30, 2004. Details available at http://www.exetersoftware.com/cat/cyrillic/cyrillic.html
11. Evans DGR, Fentiman IS, McPherson K, Asbury D, Ponder BAJ, Howell A (1994) Familial breast cancer. British Med J 308: 183-187
12. Evans DGR, Lalloo F (2002) Risk assessment and management of high risk familial breast cancer. J Med Genet 39:865-871 (Pubitemid 36009146)
13. Lalloo F, Kerr B, Friedman J, Evans DGR (2005) Risk estimation for breast cancer. In: Evans DGR, Kerr B, Lalloo F, Friedman J (eds) Risk assessment and management in cancer genetics. Oxford University Press, Oxford, pp 47-64
14. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER (2008) Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting. BMC Cancer 8(1):155
15. McIntosh A, Shaw C, Evans G, Turnbull N, Bahar N, Barclay M, Easton D, Emery J, Gray J, Halpin J, Hopwood P, McKay J, Sheppard C, Sibbering M, Watson W, Wailoo A, Hutchinson A (2004 updated 2006) Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. National Collaborating Centre for Primary Care/University of Sheffield, London. NICE guideline CG041. www.nice.org.uk
16. Breslow NE, Day NE (1987) Statistical methods in cancer research Vol II. The design and analysis of cohort studies (IARC) Scientific Publication No 82. International Agency for Research on Cancer, Lyon
17. Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. Lancet 358:1389-1399
18. https://pluto.srl.cam.ac.uk/cgi-bin/bd2/v2/bd.cgi. Accessed 9 August 2013
19. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, Easton DF (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98(12):2015
20. Norman RP, Evans DG, Easton DF, Young KC (2007) The costutility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49. Eur J Health Econ 8(2):137-144 (Pubitemid 46742897)
21. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA, American Cancer Society Breast Cancer Advisory Group (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75-89 (Pubitemid 46535708)
22. Evans DGR, Lennard F, Pointon LJ, Ramus SJ, Gayther SA, Sodha N, Kwan-Lim GE, Leach MO, Warren R, Thompson D, Easton DF, Eeles R, On behalf of The UK study of MRI screening for breast cancer in women at high risk (MARIBS) (2009) Eligibility for MRI screening in the UK: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS study. Cancer Epid Biomarkers Prev 18(7):2123-2131
23. Ozanne EM, Drohan B, Bosinoff P, Semine A, Jellinek M, Cronin C, Millham F, Dowd D, Rourke T, Block C, Hughes KS (2013) Which risk model to use? Clinical implications of the ACS MRI screening guidelines. Cancer Epidemiol Biomarkers Prev 22(1):146-149
24. Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ (2009) Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat 115(2):381-390
25. Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB (2012) Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res 14(6):R144
26. van Asperen CJ, Jonker MA, Jacobi CE, van Diemen-Homan JE, Bakker E, Breuning MH, van Houwelingen JC, de Bock GH (2004) Risk estimation for healthy women from breast cancer families: new insights and new strategies. Cancer Epidemiol Biomarkers Prev 13(1):87-93 (Pubitemid 38116625)